Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tscan Therapeutics Inc (NQ: TCRX ) 5.040 -0.210 (-4.00%) Streaming Delayed Price Updated: 10:14 AM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tscan Therapeutics Inc < Previous 1 2 3 Next > TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update November 12, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition November 05, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting October 04, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Participate in Upcoming Investor Conferences August 29, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 12, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Updates to its Board of Directors June 14, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference May 30, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies May 29, 2024 RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update May 13, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors May 09, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting April 24, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares April 24, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting April 22, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Closing of Upsized Public Offering April 19, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering April 17, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering April 16, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities April 16, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer April 08, 2024 Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 06, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference February 28, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR February 26, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR February 14, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development February 06, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer January 29, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR January 18, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress January 04, 2024 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition December 09, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations December 07, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition December 04, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
